Teva Pharmaceutical Industries Ltd, 12, Hatrufa St, Netanya, Israel.
Rev Neurol (Paris). 2024 May;180(5):438-450. doi: 10.1016/j.neurol.2023.11.013. Epub 2024 Mar 6.
This paper aims to provide a literature overview on multiple system atrophy (MSA) prevalence in European and other pan-European populations.
A literature search (PubMed, EMBASE) was performed through 2022 to identify published studies on MSA prevalence in European countries. Of these search results, titles and abstracts were screened for relevance. A standardized assessment tool was used for systematically data extraction and comparison. For studies where only the incidence rate was reported, MSA prevalence was derived based on the incidence and duration of disease.
A total of 24 studies conducted in 14 countries and published between 1995 and 2022 were identified. The prevalence of MSA was reported in 18 (75%) studies and was derived from six (25%) incidence studies. These studies were mainly prospective population-based studies or multi-center studies from specific regions or specialty clinical settings. Two earlier studies in Germany and the Netherlands were conducted using door-to-door design. The time period of evaluation of prevalence ranged from 1990 to 2018. The crude prevalence of MSA ranged from 0.5/100,000 in Spain to 17/100,000 in Japan. Age-specific prevalence rates were provided in five studies, and the reported age ranges varied. The gender-specific crude prevalence was estimated as 2.75/100,000 for men and 1.19/100.000 for women. The derived prevalence was higher (ranging from 0.7-18.9/100,000) than studies where the prevalence was reported.
The variations observed in MSA prevalence may result from differences in age distributions of the study populations, study methodology, diagnostic criteria and case assessment strategies of MSA. Thus, the comparability of these studies is limited.
本文旨在提供一份关于欧洲及其他泛欧地区多系统萎缩(MSA)患病率的文献综述。
通过 2022 年的文献检索(PubMed、EMBASE),检索了发表在欧洲国家的 MSA 患病率的研究。对这些检索结果的标题和摘要进行了相关性筛选。使用标准化评估工具进行系统的数据提取和比较。对于仅报告发病率的研究,根据疾病的发病率和持续时间推导出 MSA 的患病率。
共确定了 24 项在 14 个国家进行的研究,发表时间在 1995 年至 2022 年之间。18 项(75%)研究报告了 MSA 的患病率,其中 6 项(25%)研究是基于发病率研究推导得出的。这些研究主要是前瞻性的基于人群的研究或特定地区或专业临床环境的多中心研究。德国和荷兰的两项较早的研究采用了逐户上门的设计。患病率评估的时间范围从 1990 年至 2018 年不等。MSA 的粗患病率从西班牙的 0.5/100,000 到日本的 17/100,000 不等。有 5 项研究提供了年龄特异性患病率,报告的年龄范围不同。估计男性的性别特异性粗患病率为 2.75/100,000,女性为 1.19/100,000。推导的患病率高于报告患病率的研究(范围为 0.7-18.9/100,000)。
MSA 患病率的差异可能是由于研究人群的年龄分布、研究方法、MSA 的诊断标准和病例评估策略的不同造成的。因此,这些研究的可比性有限。